USNA on NYSE

USANA Health Sciences

American direct sales company

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility.3 It was founded by Myron W. Wentz.1 Its shares trade on NYSE under the symbol USNA.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$925.3MRevenue, fiscal 20265
$10.8MNet income, fiscal 20265
1992Founded1

Compare with Tilray, Trulieve Cannabis Corp. or Curaleaf, or pick any stock.

  • TickerUSNA on NYSE1
  • Industryfood industry1
  • HeadquartersSalt Lake City1
  • Founded inWest Valley City1
  • Websitewww.usana.com
  • Incorporated inUT6
  • Business address3838 West Parkway Blvd., Salt Lake City, Ut 84120-63366
  • Filer categoryAccelerated filer6
  • Legal formProfit Corporation4
  • LEI549300YTURXE814MAH964
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 84101 Salt Lake City, United States4
  • Registered withUtah Division of Corporations & Commercial Code (Department of Commerce), 1175041-01424
Green-Marque
Photo: USANA Health Sciences, CC BY-SA 3.0, via Wikimedia Commons9

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

78.3%Gross margin5
4.0%Operating margin5
1.2%Net margin5
2.0%Return on equity5
$8.5MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Core Nutritional brought in 84% of the revenue USANA Health Sciences broke down this way in fiscal 2025.

  1. Core Nutritional$775.5M584%down 8% from 2024
  2. Hiya$132.0M514%up 6599% from 2024
  3. All Other$17.8M52%up 164% from 2024
Business segments by year
Business segments202320242025
Core Nutritional$915.2M$845.8M$775.5M
Hiya$2.0M$132.0M
All Other$5.8M$6.7M$17.8M

Regions

Greater China brought in 27% of the revenue USANA Health Sciences broke down this way in fiscal 2025.

  1. Greater China$424.5M527%down 7% from 2024
  2. [Canada]$381.8M524%down 8% from 2024
  3. Americas And Europe$298.1M519%up 74% from 2024
  4. United States$224.9M514%up 145% from 2024
  5. Southeast Asia Pacific$132.0M58%down 10% from 2024
  6. North Asia$70.6M54%down 10% from 2024
  7. South Korea$68.9M54%down 10% from 2024
Regions by year
Regions202320242025
Greater China$475.1M$458.0M$424.5M
[Canada]$427.3M$413.5M$381.8M
Americas And Europe$180.6M$171.5M$298.1M
United States$95.9M$91.8M$224.9M
Southeast Asia Pacific$163.9M$146.8M$132.0M
North Asia$101.4M$78.2M$70.6M
South Korea$99.1M$76.4M$68.9M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue22¢$200.9M
  • Research and development1¢$10.7M
  • Selling, general and admin36¢$337.4M
  • Other costs36¢$335.5M
  • Income tax3¢$30.1M
  • Profit1¢$10.8M

Out of $925.3M in revenue.5

Where each dollar of operating cash went, fiscal 2026

  • Capital spending33¢$13.8M
  • Share buybacks67¢$27.5M

Out of $22.3M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5

Financial statements

Revenue1011125$925.3M in 2026−13% since 2019
0$500.0M$1.0B$1.5B2019: $1.1B$1.1B20192021: $1.1B$1.1B2021+7%2022: $998.6M$998.6M2022−12%2023: $921.0M$921.0M2023−8%2024: $854.5M$854.5M2024−7%2026: $925.3M$925.3M2026+8%
Gross profit1011125$724.4M in 2026−17% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $873.4M$873.4M20192021: $925.5M$925.5M2021+6%2022: $804.7M$804.7M2022−13%2023: $744.3M$744.3M2023−8%2024: $693.3M$693.3M2024−7%2026: $724.4M$724.4M2026+4%
Operating income1011125$37.4M in 2026−74% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $146.2M$146.2M20192021: $176.5M$176.5M2021+21%2022: $107.6M$107.6M2022−39%2023: $93.1M$93.1M2023−14%2024: $66.3M$66.3M2024−29%2026: $37.4M$37.4M2026−44%
Net income1011125$10.8M in 2026−89% since 2019
0$50.0M$100.0M$150.0M2019: $100.5M$100.5M20192021: $124.7M$124.7M2021+24%2022: $69.3M$69.3M2022−44%2023: $63.8M$63.8M2023−8%2024: $42.0M$42.0M2024−34%2026: $10.8M$10.8M2026−74%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Net sales$925.3M$854.5M$921.0M
Cost of sales$200.9M$161.2M$176.7M
Gross profit$724.4M$693.3M$744.3M
Brand Partner incentives$336.2M$363.7M$394.3M
Selling, general and administrative$337.4M$263.3M$257.0M
Impairment$7.0M$0$0
Cost realignment$6.5M$0$0
Total operating expenses$687.0M$627.0M$651.2M
Earnings from operations$37.4M$66.3M$93.1M
Interest income$2.4M$11.3M$9.6M
Interest expense-$842.0K-$281.0K-$262.0K
Other, net$2.5M-$1.0M$7.0K
Other income (expense), net$4.1M$10.0M$9.4M
Earnings before income taxes$41.5M$76.4M$102.5M
Income taxes$30.1M$34.3M$38.7M
Net earnings$11.5M$42.1M$63.8M
Less: Net earnings attributable to redeemable noncontrolling interest$717.0K$30.0K$0
Net earnings attributable to USANA$10.8M$42.0M$63.8M
Basic (in dollars per share)$0.58$2.20$3.31
Diluted (in dollars per share)$0.58$2.19$3.30
Basic (in shares)18.5M shares19.1M shares19.2M shares
Diluted (in shares)18.6M shares19.2M shares19.3M shares
Foreign currency translation adjustment$7.2M-$9.4M-$1.3M
Tax benefit (expense) related to foreign currency translation adjustment-$658.0K$434.0K$390.0K
Other comprehensive income (loss), net of tax$6.5M-$9.0M-$908.0K
Comprehensive income$18.0M$33.1M$62.9M
Less: comprehensive income attributable to redeemable noncontrolling interest$717.0K$30.0K$0
Comprehensive income attributable to USANA$17.3M$33.1M$62.9M

Compare USANA Health Sciences with another company

Corporate structure

USANA Health Sciences sits at the top of its group. 29 entities, 16 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of USANA Health Sciences

  • RENAISSANCE TECHNOLOGIES LLC Filed SCHEDULE 13G/A on USANA Health Sciences, latest Aug 13, 2026 (4 filings since Feb 11, 2022)
  • Myron W. Wentz Filed SCHEDULE 13D/A on USANA Health Sciences, latest Mar 30, 2026 (2 filings since Nov 22, 2021)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on USANA Health Sciences, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
  • BlackRock Filed SCHEDULE 13G/A on USANA Health Sciences, latest Jan 21, 2026 (4 filings since Feb 1, 2022)
  • DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on USANA Health Sciences, latest Jan 21, 2026 (2 filings since Oct 9, 2025)
  • PZENA INVESTMENT MANAGEMENT LLC Filed SCHEDULE 13G/A on USANA Health Sciences, latest Oct 14, 2025 (2 filings since Oct 21, 2024)
  • USANA Health Sciences Salt Lake City, Utah, United States
    • Hiya Health Subsidiary · Los Angeles, United States
    • Hiya Health Products, LLC Subsidiary · Delaware, United States
    • International Holdings, Inc. Subsidiary · Delaware, United States
    • OOLA Life, Inc. Subsidiary · Utah, United States
    • Pet Lane, Inc. Subsidiary · Delaware, United States
    • PT. USANA Health Sciences Indonesia Subsidiary · Indonesia
    • PT. USANA International Indonesia Subsidiary · Indonesia
    • Rise Wellness, Inc. Subsidiary · Utah, United States
    • UHS Essential Health (Malaysia) SND BHD Subsidiary · Malaysia
    • UHS Essential Health Philippines, Inc. Subsidiary · Utah, United States
    • USANA Air LLC Subsidiary · Utah, United States
    • USANA Asia Holding Pte. Ltd. Subsidiary · Singapore
    • USANA Australia Pty Ltd Subsidiary · Australia
    • USANA Canada Co. Subsidiary · Canada
    • USANA Canada Holding, Inc. Subsidiary · Delaware, United States
    • USANA Europe GmbH Subsidiary · Germany
    • USANA Health Sciences (Colombia) S.A.S. Subsidiary · Colombia
    • USANA Health Sciences (France) SAS Subsidiary · France
    • USANA Health Sciences (NZ) Corporation Subsidiary · New Zealand
    • USANA Health Sciences (Thailand) Ltd Subsidiary · Thailand
    • USANA Health Sciences China, Inc. Subsidiary · Delaware, United States
    • USANA HEALTH SCIENCES INDIA PRIVATE LIMITED Subsidiary · Delhi, India
    • USANA Health Sciences Japan, LLC Subsidiary · Japan
    • USANA Health Sciences Korea, Ltd. Subsidiary · South Korea
    • USANA Health Sciences New Zealand, Inc. Subsidiary · Delaware, United States
    • and 3 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What USANA Health Sciences reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$134.6M5 Jan 3, 2026$130.1M5 Dec 28, 2024+3.5%
Property and equipment, net$94.4M5 Jan 3, 2026$94.6M5 Dec 28, 2024−0.2%
Operating-lease assets (leased space)$23.0M5 Jan 3, 2026$21.2M5 Dec 28, 2024+8.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$158.4M5 Jan 3, 2026$181.8M5 Dec 28, 2024−12.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$138.0M5 Jan 3, 2026$144.2M5 Dec 28, 2024−4.3%
Intangible assets, net (excluding goodwill)$133.2M5 Jan 3, 2026$151.8M5 Dec 28, 2024−12.3%
Finite-lived intangibles, gross$137.3M5 Jan 3, 2026$138.5M5 Dec 28, 2024−0.9%
Accumulated amortization$30.0M5 Jan 3, 2026$11.5M5 Dec 28, 2024+161.8%
Finite-lived intangibles, net$107.3M5 Jan 3, 2026$127.0M5 Dec 28, 2024−15.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$102.6M5 Jan 3, 2026$69.7M5 Dec 28, 2024+47.1%
Raw materials$31.7M5 Jan 3, 2026$24.5M5 Dec 28, 2024+29.7%
Work in process$5.0M5 Jan 3, 2026$3.6M5 Dec 28, 2024+38.5%
Finished goods$65.9M5 Jan 3, 2026$41.7M5 Dec 28, 2024+58.1%

Properties, in its own words

Corporate Headquarters

Our worldwide corporate headquarters is a 354,000 square foot company-owned facility located in Salt Lake City, Utah. In addition to executive offices, this facility includes space for manufacturing and quality control, distribution, administrative functions, and research and development. This facility manufactures inventories for all global core nutritional markets, excluding China and India as well as certain inventories for Hiya and Rise. Additionally, we own a 54,000 square foot manufacturing facility, located adjacent to the corporate headquarters facility, where we manufacture certain of our foods products.

The rest of Item 2

China Manufacturing

We own a 350,000 square foot state-of-the-art facility in Beijing, China similar in potential capacity and nature to our corporate headquarters to manufacture products sold in China. Additionally, we own a 31,000 square foot manufacturing facility in Tianjin, China, where we manufacture our skincare products for sale in China.

Other Office and Distribution Warehouse Facilities

We own a 45,000 square foot office and warehouse building in Sydney, Australia.

In other markets, we lease regional offices and distribution warehouses. Additionally, we lease retail centers for our operations in China.

We believe that the facilities referenced above are in good condition and are adequately utilized. Further, we believe that our current and planned manufacturing facilities provide for the productive capacity to meet our foreseeable needs.

Item 2 of the 10-K filed Mar 16, 2026.17

The story

Founded by Myron W. Wentz in 1992, in West Valley City.1

In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.

On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.

In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.

USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.

In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.

By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.

The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.

In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.

Read the full text

In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.

From Wikipedia’s article on USANA Health Sciences, shared under CC BY-SA 4.0.7

Leadership

Who has led USANA Health Sciences, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (31)

Products and brands

USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).

USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.

USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.

From Wikipedia’s article on USANA Health Sciences, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • Hiya Health Products, LLC Delaware8
  • International Holdings, Inc. Delaware8
  • OOLA Life, Inc. Utah8
  • PT. USANA Health Sciences Indonesia Indonesia8
  • PT. USANA International Indonesia Indonesia8
  • Pet Lane, Inc. Delaware8
  • Rise Wellness, Inc. Utah8
  • UHS Essential Health (Malaysia) SND BHD Malaysia8
  • UHS Essential Health Philippines, Inc. Utah8
  • USANA Air LLC Utah8
  • USANA Asia Holding Pte. Ltd. Singapore8
  • USANA Australia Pty Ltd Australia8
  • USANA Canada Co. Canada8
  • USANA Canada Holding, Inc. Delaware8
  • USANA Europe GmbH Germany8
  • USANA Health Sciences (Colombia) S.A.S. Colombia8
  • USANA Health Sciences (France) SAS France8
  • USANA Health Sciences (NZ) Corporation New Zealand8
  • USANA Health Sciences (Thailand) Ltd Thailand8
  • USANA Health Sciences China, Inc. Delaware8
  • USANA Health Sciences India Private Limited India8
  • USANA Health Sciences Japan, LLC Japan8
  • USANA Health Sciences Korea, Ltd. South Korea8
  • USANA Health Sciences New Zealand, Inc. Delaware8
All 27 listed subsidiaries
  • USANA Health Sciences Singapore Pte. Ltd. Singapore8
  • USANA Hong Kong Limited Hong Kong8
  • USANA Mexico S. de R.L. de C.V. Mexico8

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • USANA INCJul 23, 1996 to Apr 27, 20006

Timeline

  1. Oct 5, 20268-K Entered a material agreement; New debt or obligation60
  2. Aug 4, 20268-K Results of operations; Regulation FD disclosure61
  3. May 20, 20268-K Shareholder vote62
  4. May 5, 20268-K Results of operations; Regulation FD disclosure63
  5. Feb 18, 20268-K Results of operations; Regulation FD disclosure64
  6. Feb 11, 20268-K Executive or director change65
  7. Jan 12, 20268-K Results of operations; Regulation FD disclosure66
  8. Jan 8, 20268-K Executive or director change; Regulation FD disclosure67
  9. Oct 22, 20258-K Results of operations; Regulation FD disclosure68
  10. Oct 9, 20258-K Results of operations; Regulation FD disclosure69
  11. Jul 22, 20258-K Results of operations; Regulation FD disclosure70
  12. Jul 1, 20258-K Entered a material agreement; New debt or obligation71
  13. Feb 7, 2023New chief executive Kevin Guest becomes CEO18
  14. Feb 14, 2007New chief executive Myron W. Wentz becomes CEO19
  15. May 30, 1996Went public Listed on NYSE1
  16. 1992Founded Founded in West Valley City1

Calendar

Coming up

  1. Nov 3, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported ($0.15) a share, on Oct 22, 2025.72

When it reported results

  1. Aug 4, 2026Reported quarterly or annual results61
  2. May 5, 2026Reported quarterly or annual results63
  3. Feb 18, 2026Reported quarterly or annual results64
  4. Jan 12, 2026Reported quarterly or annual results66
  5. Oct 22, 2025Reported quarterly or annual results68
  6. Oct 9, 2025Reported quarterly or annual results69
  7. Jul 22, 2025Reported quarterly or annual results70
  8. Apr 22, 2025Reported quarterly or annual results73

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

579 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 424 insider forms, 20 large holders, 75 other. The latest 20:

  1. Oct 5, 20268-K EDGAR
  2. Aug 13, 2026SCHEDULE 13G/A EDGAR
  3. Aug 13, 202610-Q EDGAR
  4. Aug 4, 20268-K EDGAR
  5. Jul 27, 20264 EDGAR
  6. Jul 27, 20264 EDGAR
  7. Jul 27, 20264 EDGAR
  8. Jul 27, 20264 EDGAR
  9. Jul 27, 20264 EDGAR
  10. Jul 27, 20264 EDGAR
  11. Jul 27, 20264 EDGAR
  12. Jul 27, 20264 EDGAR
  13. Jul 27, 20264 EDGAR
  14. Jun 18, 20264 EDGAR
  15. Jun 16, 2026144 EDGAR
  16. Jun 16, 20264 EDGAR
  17. Jun 15, 2026144 EDGAR
  18. Jun 15, 202611-K EDGAR
  19. Jun 8, 2026144 EDGAR
  20. Jun 8, 20264 EDGAR

The 579 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

110 open-market trades by officers, directors and large owners since October 2021: 0 buys and 110 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 16, 2026Neidig BrentCHIEF COMMERCIAL OFFICERSale5,002$19.45$97.3KForm 4
Jun 15, 2026Neidig BrentCHIEF COMMERCIAL OFFICERSale909$20.01$18.2KForm 4
Jun 12, 2026Neidig BrentCHIEF COMMERCIAL OFFICERSale1,602$20.15$32.3KForm 4
Jun 8, 2026Jones Paul A.CHIEF PEOPLE OFFICERSale5,561$18.50$102.9KForm 4
Jun 1, 2026Fleming John TurmanDirectorSale2,450$17.93$43.9KForm 4
May 28, 2026Jones Paul A.CHIEF PEOPLE OFFICERSale6,813$18.95$129.1KForm 4
May 27, 2026IIEKKING G DOUGCHIEF FINANCIAL OFFICERSale5,360$18.75$100.5KForm 4
May 22, 2026FULLER GILBERT ADirectorSale1,057$18.66$19.7KForm 4
May 7, 2026Foukas JoshuaCHIEF LEGAL OFFICERSale3,791$19.82$75.1KForm 4
Mar 20, 2026FULLER GILBERT ADirectorSale1,058$17.00$18.0KForm 4
Mar 3, 2026Benedict PeterCHIEF INFORMATION OFFICERSale4,553$19.38$88.2KForm 4
Feb 20, 2026Foukas JoshuaCHIEF LEGAL OFFICERSale4,461$21.35$95.2KForm 4
Dec 10, 2025Benedict PeterCHIEF INFORMATION OFFICERSale2,673$20.95$56.0KForm 4
Dec 10, 2025Mulham David MulhamCHIEF SALES OFFICERSale873$21.00$18.3KForm 4
Nov 10, 2025Winssinger Frederic JDirectorSale2,000$19.21$38.4KForm 4
Nov 3, 2025FULLER GILBERT ADirectorSale1,057$21.48$22.7KForm 4
Oct 31, 2025Fleming John TurmanDirectorSale1,750$19.79$34.6KForm 4
Aug 7, 2025FULLER GILBERT ADirectorSale1,058$29.10$30.8KForm 4
Jul 30, 2025Mulham David MulhamCHIEF SALES OFFICERSale3,515$30.26$106.4KForm 4
Jun 9, 2025Fleming John TurmanDirectorSale500$29.66$14.8KForm 4

All 110 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Jim H. Brown,$821.2K$4.3M80
2025Walter Noot,$564.9K$1.7M80
2025G. Douglas Hekking$568.5K$1.7M80
2025Joshua Foukas,$500.6K$1.5M80
2025Brent Neidig,$513.5K$1.4M80
2024Chief Executive Officer & President (former)$800.0K$3.4M80
2024Chief Financial Officer$553.8K$1.4M80
2024Chief Operating Officer$550.3K$1.4M80
2024Chief Commercial Officer$500.2K$1.3M80
2024Chief Legal Officer & General Counsel$487.6K$1.3M80
2023Chief Executive Officer & President (former)$709.9K$2.5M80
2023Chief Financial Officer$553.8K$1.5M80
2023Chief Operating Officer$535.6K$1.4M80
2023Chief Legal Officer & General Counsel$487.6K$1.3M80
2023Chief Commercial Officer$455.5K$1.0M80

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC1,620,148$34.6M1.1%+810,074
BlackRock, Inc.1,554,189$33.2M0.0%+363,773
Pzena Investment Management LLC1,205,587$25.7M0.1%+96,654
Renaissance Technologies LLC958,520$20.5M0.0%−59,110
Dimensional Fund Advisors LP837,426$17.9M0.0%+3,203
Vanguard Capital Management LLC487,370$10.4M0.0%+8,327
Creative Planning417,971$8.9M0.0%+224,823
Aqr Capital Management LLC408,086$8.7M0.0%+111,666
Vanguard Portfolio Management LLC363,377$7.8M0.0%+25,103
Geode Capital Management, LLC283,165$6.0M0.0%+18,731
Charles Schwab Investment Management Inc272,208$5.8M0.0%−60,904
State Street Corp261,240$5.6M0.0%+13,205
Nuveen, LLC239,477$5.1M0.0%+216,998
American Century Companies Inc187,348$4.0M0.0%−3,604
Jacobs Levy Equity Management, Inc180,567$3.9M0.0%−12,409
Two Sigma Investments, LP165,514$3.5M0.0%+20,884
Morgan Stanley164,363$3.5M0.0%+8,879
D. E. Shaw & Co., Inc.156,835$3.3M0.0%−25,648
Allianz Asset Management GmbH142,399$3.0M0.0%+24,900
Bridgeway Capital Management, LLC138,153$2.9M0.1%+39,060
Algert Global LLC131,758$2.8M0.0%+63,074
Goldman Sachs Group Inc123,267$2.6M0.0%+32,118
UBS Group AG115,886$2.5M0.0%+92,174
Lazard Asset Management LLC97,311$2.1M0.0%+24,916
Northern Trust Corp94,467$2.0M0.0%−3,900

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How USANA Health Sciences is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUSANA HEALTH SCIENCES INC2
  • CIK0000896264
  • Employer ID (EIN)87-050030617
  • Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inUtah17
  • Fiscal year endsJanuary 32
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address3838 West Parkway Blvd., Salt Lake City, UT 84120-63362
  • Mailing address3838 West Parkway Blvd., 3838 West Parkway Blvd., Salt Lake City, UT 84120-63362
  • Phone80195471002
  • Shares outstanding18,476,534 as of Aug 11, 202614
  • Public float$328.0M as of Jun 27, 202517
  • AuditorKPMG LLP, Salt Lake City, Utah PCAOB ID 185; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceMay 15, 19962
  • Filings2,091 in all: 4 (1,361), 8-K (205), 10-Q (89), 144 (53), 3 (43), SC 13G/A (41), 5 (36), DEF 14A (32)2
    All 51 form types

    10-K (28), 4/A (26), 11-K (22), UPLOAD (17), DEFA14A (16), SC 13G (16), CORRESP (14), SC 13D/A (10), SCHEDULE 13G/A (7), 8-K/A (6), S-8 (6), ARS (5), PRE 14A (5), SC 13E3/A (5), 10QSB (3), 3/A (3), SC 14D9/A (3), SC TO-T/A (3), 10-K/A (2), 10-Q/A (2), 10QSB/A (2), 5/A (2), POS AM (2), S-3 (2), S-8 POS (2), SC 13D (2), SC 14D9 (2), SC TO-C (2), SCHEDULE 13G (2), 10-K405 (1), 10-K405/A (1), 10KSB40 (1), 10KSB40/A (1), 25 (1), 8-A12B (1), CERTNYS (1), EFFECT (1), NT 10-K (1), PRES14A (1), SC 13E3 (1), SC TO-T (1), SC14D9C (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 7, 2026
    Latest 8-K (8-K) Oct 5, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, Par Value $0.001 per shareUSNANew York Stock Exchange

From the cover page of the 10-K filed Mar 16, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks USANA Health Sciences names in Item 1A of its 10-K filed Mar 16, 2026: 48 risks under these headings, as written.17

  • Risks Associated with Direct Selling
  • Risks Related to Our China Business
  • Risk Associated with Our International Operations
  • Risks Related to Our Products, Manufacturing and Operations
  • Legal, Regulatory, Compliance and Tax Risks
  • Risk Associated with Information Technology, Data Security and Data Privacy
  • Human Capital Risks Associated with our Business
  • Risks Associated with Business Development Activities and Acquisitions
  • General Economic, Publicity, Competitive, and Intellectual Property Risks Associated with our Business
  • Risks Related to Public Health Crises
  • Risks Related to Our Common Stock
  • Risk Associated with Direct Selling
The other 46 risks
  • Direct selling is subject to intense government scrutiny, and regulation and changes in the law, or the interpretation and enforcement of the law, might adversely affect our business.
  • The violation of marketing or advertising laws by Brand Partners in connection with the sale of our products or the improper promotion of our Compensation Plan could adversely affect our business.
  • We may have or could incur obligations relating to the activities of our Brand Partners.
  • Our Brand Partner Compensation Plan, or changes we make to it, may be viewed negatively by some Brand Partners, could fail to achieve our desired objectives, and could have a negative impact on our business.
  • Changes we are required to make to our Brand Partner Compensation Plan in certain markets, including limits on the amount of Brand Partner compensation we can pay, may hurt our ability to attract and retain Brand Partners, result in regulatory risk and affect our operating results.
  • Our Greater China region accounts for a significant part of our business and expected growth. A decline in sales or customers in this region would harm our business, financial condition and results of operations.
  • Our operations in China are subject to significant government regulation, as well as a variety of legal, political, and economic risks. If the Chinese government modifies its direct selling laws and regulations, or interprets and enforces these laws and regulations in a manner that is adverse to our business in China, our consolidated business and results of operations may be materially harmed.
  • Although BabyCare utilizes a business model that has been developed specifically for China’s laws and regulations, the Chinese government has not approved BabyCare’s model, compensation plan, and operations.
  • BabyCare’s operations in China, and direct selling companies in general, are subject to significant government oversight, scrutiny and monitoring.
  • BabyCare must apply for and receive government approval to expand its business in China and the failure to obtain such approvals could negatively impact its ability to expand and grow its business.
  • Risks associated with operating in international markets could restrict our ability to expand globally and harm our business and prospects.
  • Trade policies, disputes, tariffs or other international disputes could harm our business and operating results.
  • We are subject to various governmental export control and trade sanctions laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate these controls.
  • Fluctuation in the value of currency exchange rates with the U.S. dollar affects our operations and our net sales and earnings.
  • Inflationary pressures and persistently high prices and uncertain availability of commodities, raw materials or other inputs used by us and our suppliers, or instability in logistics and related costs, could negatively impact our profitability.
  • Our products and manufacturing activities are subject to extensive government regulation, which could limit or prevent the sale of our products in some markets.
  • Our in-house manufacturing activity is subject to certain risks.
  • Our reliance on third parties to manufacture and supply certain of our products may harm our business, financial condition and operating results.
  • The inability to obtain adequate supplies of raw materials for products at favorable prices, or at all, could have a material adverse effect on our business, financial condition, or operating results.
  • Delays and disruptions to transporting and distributing our products may adversely affect our results.
  • We may incur liability with respect to our products.
  • Nutritional supplement products may be supported by only limited availability of conclusive clinical studies.
  • Legal action by former Brand Partners or third parties against us could harm our business.
  • We may incur liability under our “Athlete Guarantee” program.
  • Failure to comply with anti-corruption laws could adversely affect our business.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • Our effective tax rate has meaningfully increased over the last few years and will likely remain elevated due to profitability erosion in the U.S. resulting from geographic misalignment between net sales and operating expenses.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud.
  • Environmental, Social and Governance ("ESG") issues may have an adverse effect on our reputation, business, financial condition or results of operations.
  • A failure or interruption of our information technology systems would harm our business.
  • We rely on information technology to support our operations and reporting environments. A data breach involving that technology or the data stored in it, could disrupt our ability to operate our businesses effectively, adversely affect our reported financial results and our reputation, and expose us to significant potential liability, government investigations, fines or litigation.
  • We are subject to data privacy and security laws and regulations, and our actual or perceived failure to comply with them could adversely affect our business and operating results.
  • If we are unable to attract and retain active Brand Partners and Preferred Customers, our business may be harmed.
  • The loss of key management personnel could adversely affect our business.
  • Risks Associated with Business Development Activities, Acquisitions and our Acquired Businesses
  • Growth through acquisitions is part of our strategy, and we may not successfully integrate, operate or realize the anticipated benefits of our acquisitions.
  • Although we expect that the Hiya Acquisition will result in synergies and other benefits to us, we may not realize those benefits because of challenges inherently associated with integration, performance and the achievement of synergies.
  • The Hiya Acquisition and integration may result in additional costs and expenses.
  • The Hiya Acquisition may be viewed negatively by our Brand Partners.
  • Hiya's ability to acquire customers in a cost effective manner depends on its capacity to adapt to changes in the digital marketing environment.
  • Rise's business depends on a limited number of key retail customers, and the loss of, or a significant reduction in orders from, any of these customers could materially adversely affect Rise's business, financial condition and results of operations.
  • Difficult economic conditions may adversely affect our business.
  • Risks Associated with Public Health Crises
  • Pandemics, epidemics, disease outbreaks and other public health crises, such as the COVID-19 pandemic, have disrupted our business and operations, and future public health crises could materially adversely impact our business, financial condition, liquidity and results of operations.
  • The beneficial ownership of a significant percentage of our common stock gives our founder and parties related to or affiliated with him effective control, and limits the influence of other shareholders on important policy and management issues.
  • Sales by our shareholders of a substantial number of shares of our common stock in the public market could adversely affect the market price of our common stock.
  • The market price of our common stock may be influenced by many factors, some of which are beyond our control.

Legal proceedings

We are a party to litigation and other proceedings that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters.

Information with respect to legal proceedings may be found in Note K to the consolidated financial statements included in Part II, Item 8 of this Annual Report, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80